1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

11.13
BRL
0.00
(0.00%)
0.46EPS
27.78P/E
63.39BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
26.13
29.25
30.49
28.57
28.8
31.18
35.42
38.47
43.46
49.8
56.42
65.71
67.85
84.36
Basic EPS, GAAP
4.25
4.38
3.94
2.44
1.99
3.81
3.96
3.5
4.78
9.13
11.25
11.41
8.65
8.44
Free Cash Flow per Basic Share
1.75
1.92
5.2
-3.95
1.42
4.12
4.81
4.69
1.84
8.1
3.64
2.43
3.7
2.35
Dividend per Share
0.59
0.71
0.81
0.69
0.81
0.81
0.79
0.84
0.84
1.01
1.34
1.34
1.34
1.7
Book Value per Share
17.95
21.97
25.3
25.17
25.63
28.43
31.44
35.12
38.61
46.75
56.65
67.37
76.14
77.39
Tangible Book Value per Share
15.04
18.72
20.44
15.29
15.78
18.64
25.02
26.96
32.19
39.65
48.33
45.42
52.32
53.89
Basic Weighted Avg Shares
5,059
5,067
5,074
4,929
4,932
4,934
4,930
4,932
4,933
4,938
4,948
4,954
4,951
3,926
Sales/Revenue/Turnover
132,170
148,189
154,708
140,809
142,028
153,851
174,600
189,722
214,391
245,879
279,164
325,535
335,933
331,186
Operating Margin (%)
19.66
17.84
19.22
9.64
8.47
12.89
18.77
17.35
16.75
24.02
23.39
22.12
14.92
10.89
Depreciation Expense
7,106
8,100
10,250
11,277
11,710
12,190
12,472
12,796
11,824
12,636
14,841
17,058
20,605
21,212
Net Income, GAAP
21,515
22,179
20,013
12,039
9,806
18,795
19,498
17,238
23,568
45,067
55,684
56,544
42,850
33,114
Effective Tax Rate (%)
19.15
21.25
26.26
17.84
31.62
16.25
- -
34.74
27.03
25.34
22.52
25.45
22.53
20.77
Profit Margin (%)
16.28
14.97
12.94
8.55
6.9
12.22
11.17
9.09
10.99
18.33
19.95
17.37
12.76
10
Working Capital
49,684
55,843
55,042
15,375
39,953
54,801
57,556
64,858
87,841
118,408
152,010
119,720
134,409
141,990
LT Debt
20,740
14,307
10,685
5,449
25,089
22,000
1,304
6,299
5,746
1,278
5,990
7,864
12,203
11,884
Total Equity
90,801
111,302
128,336
124,044
126,460
140,197
154,988
173,062
190,527
230,991
280,550
337,166
380,457
386,735
Return on Invested Capital (%)
17.11
14.16
13.65
6.57
4.64
9.85
- -
8.34
10.04
18.15
19.19
15.59
9.26
6.06
Return on Capital (%)
18.4
15.89
13.04
7.5
5.9
10.98
- -
9.39
11.35
19.68
20.92
16.93
10.96
8.55
Return on Common Equity (%)
26.3
21.95
16.7
9.54
7.83
14.1
13.21
10.51
12.96
21.38
21.77
18.42
12.06
9.03

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
56,124
65,138
60,068
LT Borrowings
- -
12,203
- -
LT Finance Leases
11,608
12,203
11,884
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,952
4,953
4,954
Market Capitalization
984,424
1,051,342
1,160,807

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
297,549
301,975
299,331
Cash, Cash Equivalents & STI
82,589
87,814
81,427
Accounts Receivable, Net
103,206
101,219
100,557
Inventories
79,009
76,531
80,473
Total Current Liabilities
158,310
167,566
157,341
Payables & Accruals
84,552
77,160
78,406
ST Debt
56,124
65,138
60,068
Deferred Revenue
1,780
1,581
1,744

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.75%
17.16%
12.84%
Free Cash Flow
14.05%
49%
52.37%
Net Income, GAAP
15.43%
25.76%
-24.22%
Sales/Revenue/Turnover
8.34%
12.21%
3.19%
Total Cash Common Dividend
5.81%
10.75%
-0.05%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
76,727
80,162
83,586
85,060
325,535
2026
85,452
88,051
87,268
75,162
335,933
2027
80,705
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.81
2.53
2.85
3.21
11.41
2026
2.87
17.22
2.44
0.45
8.65
2027
0.89
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
1.34
- -
- -
1.34
2026
- -
7.98
- -
- -
1.34
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Erez Israeli
Full Time Employees
27,527
Sector
Health technology
Industry
Pharmaceuticals: major
Address
8-2-337, Road No. 3 Hyderabad TS India 500034
IPO Date
Jan 1, 1986
Website
drreddys.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Divi's Laboratories Limited (NSE:DIVISLAB)
Merck & Company, Inc. (NYSE:MRK)
Business
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company that develops, manufactures and markets generics, active pharmaceutical ingredients, biosimilars, branded generics and over-the-counter products worldwide; it offers finished dosage formulations including tablets, capsules, injectables and topical creams across therapeutic areas such as gastroenterology, cardiovascular, oncology, pain management, anti-infectives, diabetology, dermatology and pediatrics. Founded in 1984 by Kallam Anji Reddy and headquartered in Hyderabad, India, with U.S. headquarters in East Brunswick, New Jersey, the company operates manufacturing facilities in India, the UK and other regions, serving markets in North America, Europe, India, Russia and emerging economies. Its portfolio includes key active pharmaceutical ingredients like Abiraterone Acetate, Canagliflozin, Ciprofloxacin Hydrochloride, Ramipril and Ibuprofen; over 190 medications; diagnostic kits; and biotechnology products, supported by pharmaceutical services for custom development and contract manufacturing. Recent developments include a June 2025 collaboration with Alvotech to co-develop, manufacture and commercialize a pembrolizumab (Keytruda) biosimilar for global markets; acquisition of Haleon's global Nicotinell nicotine replacement therapy business (excluding the U.S.) for over Rs 5,000 crore; acquisition of U.S.-based MenoLabs to enter women's nutritional wellness; purchase of Novartis's Cidmus cardiovascular brand in India for Rs 456 crore; INR 700 crore investment in biosimilars and API capacity expansion, elevating annual capex to INR 1,400 crore; plans to launch generic weight-loss drugs in 87 countries including Canada, India and Brazil; and introduction of products like Toripalimab for nasopharyngeal carcinoma, a bevacizumab biosimilar in the UK, and Lenacapavir for HIV in partnership with Gilead Sciences.

Company News

Company News APIChatGPT

  • marketbeat.com

    Dr. Reddy's Laboratories Q2 Earnings Call Highlights

  • defenseworld.net

    Dr. Reddy’s Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • reuters.com

    India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • businesswire.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • businesswire.com

    Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • businesswire.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • gurufocus.com

    RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • businesswire.com

    RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations